Earlier Momelotinib Treatment May Improve Outcomes in Myelofibrosis
Clinical Summary:
- Design/Population: Post hoc analyses of the phase 3 SIMPLIFY-1 and MOMENTUM trials evaluated outcomes with momelotinib in patients with intermediate-1 versus intermediate-2/high-risk myelofibrosis. SIMPLIFY-1 enrolled JAK inhibitor–naïve patients, while MOMENTUM enrolled previously treated, anemic patients with myelofibrosis.
- Key Outcomes: Momelotinib demonstrated spleen, symptom, and anemia benefits across all risk categories. Response rates for several endpoints, including symptom improvement and transfusion independence, were numerically higher among patients with intermediate-1–risk disease, suggesting greater benefit when treatment is initiated earlier in the disease course.
- Clinical Relevance: These findings support the use of momelotinib across the full spectrum of approved risk categories and suggest that earlier treatment may optimize clinical outcomes in myelofibrosis.
Prithviraj Bose, MD, MD Anderson Cancer Center, Houston, Texas, discusses post hoc analyses from the phase 3 SIMPLIFY-1 and MOMENTUM trials evaluating the impact of disease risk category on outcomes with momelotinib. Although momelotinib is approved for patients with intermediate- or high-risk myelofibrosis and anemia, data specifically examining patients with intermediate-1–risk disease have been limited.
The analyses demonstrated that momelotinib provides clinically meaningful spleen, symptom, and anemia benefits regardless of risk category, with several efficacy endpoints appearing numerically more favorable in patients with intermediate-1–risk disease. These findings suggest that earlier intervention with momelotinib may improve outcomes while reinforcing its utility across the broad range of patients for whom the therapy is approved.
Dr Bose presented these results at the European Hematological Association (EHA) Annual Meeting in Stockholm, Sweden.
Source:
Bose P, O’Connell C, McLornan D, et al. Outcomes with momelotinib in patients with intermediate-1– vs intermediate-2–/high-risk myelofibrosis: Post hoc analyses of the phase 3 SIMPLIFY-1 and MOMENTUM trials. Presented at EHA Congress. June 11 - June 14, 2026. Stockholm, Sweden. Abstract EHA-3428.
